Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CME GroupCME -1.33%84 3-Year EBITDA Growth Rate is 13.10% as of Jun. 2026, which is 41% above its 10-year median of 9.30. GuruFocus rates CME with a GF Score™ of 84/100 and a GF Value™ of $271.35 (Fairly Valued). The stock has 3 warning signs investors should review. Among 511 Capital Markets companies, CME Group ranks worse than 53.03% on this metric.
During the past 12 months, CME Group's average EBITDA Per Share Growth Rate was 13.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 13.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 11.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 8.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CME Group was 105.10% per year. The lowest was -3.00% per year. And the median was 9.30% per year.
CME Group (NAS:CME) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
CME Group 3-Year EBITDA Growth Rate Related Terms
CME vs ICE, MCO, SPGI: 3-Year EBITDA Growth Rate Comparison
For the Financial Data & Stock Exchanges subindustry, CME Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CME Group 3-Year EBITDA Growth Rate vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, CME Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where CME Group's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 13.10% mean?
CME Group (CME) has a 3-Year EBITDA Growth Rate of 13.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CME Group and its competitors. This is 41% above median its historical median of 9.30. According to the industry distribution chart, CME Group ranks #271 out of 511 companies in the Capital Markets industry, placing it in the top 53%.
Is CME Group's 3-Year EBITDA Growth Rate too high?
CME Group's current 3-Year EBITDA Growth Rate of 13.10% is 41% above median its 10-year median of 9.30. The Capital Markets industry median 3-Year EBITDA Growth Rate is 14.70. CME Group's value of 13.10% is 10.9% below this industry median. Based on the distribution chart, CME Group ranks #271 out of 511 companies in the Capital Markets industry, which is below the industry midpoint. Overall, CME Group has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CME Group's 3-Year EBITDA Growth Rate compare to ICE and MCO?
According to the Capital Markets industry distribution chart, CME Group ranks #271 out of 511 companies for 3-Year EBITDA Growth Rate. This places CME Group in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.70. CME Group's value of 13.10% is 10.9% below this benchmark. While the company's 10-year median is 9.30 vs. the industry median of 14.70, CME Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Capital Markets company?
The median 3-Year EBITDA Growth Rate among Capital Markets companies is 14.70, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CME Group's current 3-Year EBITDA Growth Rate of 13.10% is 10.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for CME Group and its competitors. For the Capital Markets industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CME Group's current 3-Year EBITDA Growth Rate is 13.10%, which is 41% above median its own 10-year median of 9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CME Group stock overvalued right now?
Based on GuruFocus' analysis, CME Group (CME) is currently considered Fairly Valued. The stock's GF Value™ is $271.35, compared to a current price of $262.63 — trading 3.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 13.10%, which is 41% above median its 10-year median of 9.30 and 10.9% below the Capital Markets industry median of 14.70. CME Group's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For CME Group (CME), the current 3-Year EBITDA Growth Rate is 13.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CME Group (CME) Overvalued in 2026?
Based on GuruFocus' analysis, CME Group stock appears to be undervalued.
The current stock price of $262.63 is trading 3.2% below its estimated GF Value™ of $271.35.
GuruFocus considers CME Group to be Fairly Valued.
Key valuation signals for CME:
3-Year EBITDA Growth Rate: 13.10% (41% above median its 10-year median of 9.30)
GF Value™: $271.35 vs. price of $262.63 (3.2% below fair value)
Industry Position: 10.9% below the Capital Markets median (#271 of 511)
No single metric tells the full story. See the CME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indexes, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
84GF Score
Get the complete analysis for CME
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CME has been successfully added to your 
